期刊文献+

结直肠癌组织TP、DPD不同表达水平与XELOX化疗效果的关系及意义 被引量:2

Expressions of Thymidine Phosphorylase and Dihydropyrimidine Dehydrogenase in Colorectal Cancer and its Correlative Effects with XELOW Chemotherapy
下载PDF
导出
摘要 【目的】探讨胸腺嘧啶磷酸化酶(TP)、二氢吡啶脱氢酶(DPD)在结直肠癌组织中的表达情况及其与XELOX化疗效果的相关性。【方法】用ELISA双抗体夹心法检测58例结直肠癌患者癌组织中TP和DPD的表达量,以TP和DPD的中位数为分界,将患者分为高表达组和低表达组,患者术后均接受XELOX方案进行化疗,4个疗程后,比较不同TP和DPD的表达水平患者的早期疗效。对所有患者进行随访12~36个月,行Kaplan-Meier生存分析,比较比较不同TP和DPD的表达水平患者的预后生存情况。【结果】TP高表达组和低表达组行XELOX化疗方案的短期临床疗效相比差异无显著性(P〉0.05);TP高表达组中位生存时间显著高于低表达组(P〈0.05)。DPD高表达组XEI。OX化疗方案早期有效率及中位生存时间均低于于低表达组,差异具有统计学意义(P〈0.05)。各组患者的并发症发生情况无显著性差异(P〉0.05)。【结论】结直肠癌组织TP、DPD表达水平对XELOX化疗方案的临床疗效有关,可以作为预测XELOX化疗方案疗效的重要指标之一。 [Objective]To discuss the expressions of thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) in colorectal cancer and its correlative effects with XELOW chemotherapy. [Methods] The expressions of TP and DPD in carcinoma tissues of 58 cases were detected by double antibody sandwich of ELISA, the medians of the expressions of TP and DPD were acted as dividing lines, and the patients were divided into high expression group and low expression group, two groups of patients were treated with XELOX chemotherapy program after surgery. After four courses of therapy, the early efficacy of different TP and DPD expression levels in patients was compared. All patients were followed up for 12- 36 months, Kaplan-Meier survival analysis was conducted. The prognostic survival of patients with different TP and DPD expression levels were compared.[Results] Short-term clinical efficacy of TP high expression group and low expression group after XELOX chemotherapy had no significant difference ( P 〉0.05). The median survival time of TP high expression group was significantly higher than that of low expression group ( P 〈0.05). The efficiency and the median survival time of XELOX chemotherapy regimen in DPD high expression group were lower than those in low expression group, and the difference was statistically significant ( P 〈0.05). There was no signif- icant difference in the incidence of complications in each group ( P 〉0.05).[ConclusionlThe expression level of TP and DPD in colorectal cancer is related to the clinical efficacy of XELOX chemotherapy, and it can be used as one of the important indicators to predict the efficacy of XELOX chemotherapy.
出处 《医学临床研究》 CAS 2016年第3期494-496,500,共4页 Journal of Clinical Research
基金 常德市科技局资助项目(编号:20149k05)
关键词 结直肠肿瘤 胸腺嘧啶 磷酸化酶类/生物合成 二氢吡啶类 抗肿瘤联合化疗方案 脱氧胞苷/类似物和衍生物 脱氧胞苷/治疗应用 有机铂化合物/治疗应用 Colorectal Neoplasms Thymine Phosphorylases/BI Dihydropyridines Antineoplastic Combined Chemotherapy Protocois Deoxycytidine/AA Deoxycytidine/TU Organoplatinum Compounds/TU
  • 相关文献

参考文献8

二级参考文献61

  • 1Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capeeitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activity in tumors in human cancer xenografts [J]. Cancer Res, 1998,58 (4) : 685- 690.
  • 2Genichi N, Itsutrou T, Takashi K, et al. Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5'-deoxy-5'-fluorouridine as adjuvant chemothery [J]. Oncol Rep,2002,9(3):479 -482.
  • 3Borner MM, Dietrich D, Stupp R, et ah Phase Ⅱ study of capecitahine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer [J]. J Clin Oncol,2002,20(7):1759-1766.
  • 4Cassidy J, Tabernero J, Twelves C, et al. Xelox ( capecitabine and oxaliplatin ) : Active first-line therapy for patients with metastatic colorectal cancer [J]. J Clin Oncol,2004,22(11):2084-2091.
  • 5PARKIN D M,BRAY F,FERLAY J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 6SALONG D,DANENBERC K D,JOHNSON M,et al.Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase,thymidylate synthase,and thymidine phosphorylase[J].Clin Cancer Res,2000,6(4):1322-1327.
  • 7MEROPOL N J,COLD P J,DIASIO R B,er al.Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer[J].V Clin Oncol,2006,24(25):4069-4077.
  • 8KOOPMAN M,VENDERBOSCH S,VAN TINTEREN H,et al.Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer,a retrospective analysis of the phase Ⅲ randomised CAIRO study[J].Eur J Cancer,2009,45(11):1999-2006.
  • 9EDLER D,GLIMELIUS B,HALLSTROM M,et al.Thymidylate synthase expression in colorectal cancer:a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy[J].J Clin Oncol,2002,20(7):1721-1728.
  • 10TOKUNACA Y,SASAKI H,SAITO T.Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine[J].Surgery,2007,141(3):346-353.

共引文献21

同被引文献27

引证文献2

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部